A relevant sermorelin-service comparator with detailed public disclosures. Its introductory rate, customer survey and quality claims should each be interpreted on their own terms.
- Reviewed program
- Compounded Sermorelin Injection Rx
- Introductory wording
- $99 first month; three-month plan billed in full
- Later wording
- $149/month afterward
- Evidence boundary
- No independent program testing
What stands out
- Public explanation of clinician review and follow-up
- Survey method and sample described
- Introductory and later pricing appear on the page
What to weigh
- The lowest quote does not describe indefinite renewal
- Self-reported customer data do not prove clinical efficacy
- Exact first prepaid charge requires confirmation
The relevant comparison is sermorelin care
AgelessRx offers a wider wellness catalog, but this review concentrates on its current Sermorelin Injection program. That is the closest comparison to the corresponding CoreAge Rx offering. The service describes online clinician review, fulfillment through a licensed compounding pharmacy and ongoing messaging and adjustments.[source]
A customer comparing these providers should first understand the purpose of the proposed prescription. General fatigue, poor sleep and changing body composition are broad concerns. Their appearance in a marketing page does not establish a diagnosis or a reason that a peptide prescription is the appropriate next step.
The $99 headline has a more specific footnote
The page’s opening price is $99 per month with a three-month-plan condition. Farther down, the purchase section describes $99 for the first month, a three-month plan billed in full and $149 per month afterward. We preserve that distinction rather than advertise $99 as an indefinite monthly rate.[source]
The public wording should lead to a specific checkout question: what is the full first charge and which months use which rate? We do not infer the answer by choosing the lowest possible interpretation. Also ask what pausing or canceling does to an already paid term, and whether monitoring adds any charge.
Customer feedback is a different kind of evidence
AgelessRx links a prominent early-results claim to a survey of 392 customers who completed check-ins between August 2025 and January 2026. The page describes the data as self-reported. That is useful context for customer experience, but it is not a randomized trial of the supplied preparation or a comparison against CoreAge Rx.[source]
The page also cites third-party research involving growth-hormone signaling, different populations and different study designs. Those references should not be compressed into a promise of longer life, predictable fat loss or guaranteed improvements in sleep. This review has not verified such outcomes for the commercial program.
Separate pharmacy claims from clinical benefit
The provider describes purity, potency and sterility testing. Those are quality claims about the preparation and testing process, not proof of a treatment benefit for a particular customer. We have not independently inspected a dispensing facility or a lot-specific test report. FDA’s compounding guidance explains that compounded products are not FDA-approved.[source][source]
Ask who provides follow-up, which pharmacy dispenses and what monitoring is planned. AgelessRx may be a useful alternative for comparing the service pathway, but the evidence limitations remain part of the decision. Read our individual product review before comparing the starting price alone.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- AgelessRx: Sermorelin Injection pricing, evidence notes and safety informationManufacturer claims and a customer survey are not independent evidence of clinical benefit. The first-month price has a three-month billing condition. · Checked October 10, 2026
- FDA — Compounding and the FDA: Questions and AnswersCompounded drugs are not FDA-approved; oversight and evidence limitations · Checked October 10, 2026